Cancer Archive — Page 36 of 70
-
January 29, 2020
Protein research seeks to induce tumor regression
Understanding how MYC interacts with WDR5 and other cofactors could lead to the development of new drugs that can effectively block MYC and stop many cancers in their tracks. -
January 23, 2020
HDL-cholesterol and breast cancer risk
Genetic analyses suggest that high circulating HDL-cholesterol levels may increase breast cancer risk — a surprising finding since increased HDL-cholesterol is thought to be healthy. -
January 23, 2020
Study examines prostate cancer treatment decisions
A five-year follow-up study of more than 2,000 U.S. men who received prostate cancer treatment is creating a road map for future patients regarding long-term bowel, bladder and sexual function in order to clarify expectations and enable men to make informed choices about care. -
January 16, 2020
VUMC study sheds light on gastric cancer development
VUMC researchers have created the world’s first laboratory model of precancerous changes in the lining of the stomach, a scientific tour de force that is helping to unlock the mysteries of gastric cancer development. -
November 20, 2019
Study finds breast cancer recurrence score has different implications for men
A study published last year offered good news for women with early-stage ER-positive breast cancer who scored at intermediate risk for recurrence. However, a new study finds this conclusion may not directly apply to male patients with the same type of breast cancer -
November 14, 2019
NCI ‘Moonshot’ grant to boost hereditary cancer identification
VUMC is leading an initiative to establish a streamlined process for collection of family health histories that could set the stage for a standardized system to make the information easily accessible. -
November 7, 2019
Project seeks new way to assess immunotherapy effectiveness
GE Healthcare has awarded researchers in the Vanderbilt University Institute of Imaging Science $2.5 million in funding to develop PET tracer that will determine the effectiveness of immunotherapy in patients early in their treatment course.